Featured Firms
Presented by BigVoodoo
Brand-name drug makers have a lock on manufacturing biologics, a group of lucrative drugs used to treat diseases like cancer and diabetes. But the clock is ticking on many of their patents. And generic manufacturers are anxious to jump into the market as those patents -- estimated to be worth about $10 billion -- expire over the next few years. Now federal regulators and Congress will decide whether generic companies can safely replicate biologics, or whether such science is best left to brand-name makers.
July 14, 2004 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS